News
Combo delivers ‘impressive’ survival results in first-line RCC setting
Lenvatinib plus pembrolizumab improved progression-free and overall survival, compared with single-agent sunitinib.
News
Cabozantinib could be new standard for papillary RCC
Compared with sunitinib, cabozantinib prolonged progression-free survival in patients with metastatic disease.
News
Adjuvant nivolumab: A new standard of care in high-risk MIUC?
Nivolumab nearly doubled disease-free survival when compared with placebo.
News
Androgen annihilation strategy prolongs rPFS in mCRPC
Adding apalutamide to abiraterone and prednisone prolonged radiographic progression-free survival by 7.4 months.
News
EHR data harnessed to spot new risk factors for early-onset CRC
Machine learning models indicated that hypertension, cough, asthma, and other factors, were important in determining the risk of early-onset...
News
Test could help patients with pancreatic cysts avoid unneeded surgery
The test proved more accurate than the current standard of care.
News
Model predicts acute kidney injury in cancer patients a month in advance
A machine learning algorithm identified nearly three-quarters of patients who went on to develop acute kidney injury.
News
Test could help patients with pancreatic cysts avoid unneeded surgery
The test proved more accurate than the current standard of care.
News
AI can identify biomarkers and potentially guide therapy in NSCLC
Deep learning models accurately predicted PD-L1 positivity and EGFR mutational status in patients with non–small cell lung cancer.
News
Adaptive biomarker approach may spare some breast cancer patients chemo
The combination of recurrence score and Ki-67 response to a short preoperative course of endocrine therapy identified patients who could...
News
POP-RT trial supports whole-pelvis radiotherapy for high-risk prostate cancer
Prospective, randomized data suggest prophylactic whole-pelvis radiotherapy improves cancer outcomes without much increase in late toxicity.
News
One-week radiotherapy course should be standard for early invasive breast cancer, experts say
Two 1-week adjuvant radiotherapy regimens for breast cancer are as effective as the standard 3-week regimen, the FAST-Forward trial suggests.
News
‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer
Efficacy was poorer in node-positive and high-risk patients.